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MicroRNA-101 Exerts Tumor-Suppressive Functions in
Non-small Cell Lung Cancer through Directly Targeting
Enhancer of Zeste Homolog 2
Ji-guang Zhang, MD, PhD,* Jian-Feng Guo, MD, PhD,† Dong-Lei Liu, MD, PhD,*
Quan Liu, MD, PhD,* and Jian-Jun Wang, MD, PhD*
Introduction: Overexpression of the enhancer of zeste homolog
2 (EZH2) protein has been found in broad range of cancer types,
including non-small cell lung cancer (NSCLC). Nevertheless, the
mechanisms by which EZH2 becomes overexpressed in NSCLC
remain unclear. MicroRNAs (miRNAs) can regulate target gene
expression through translational control. In this study, we inves-
tigate whether miRNA (miR-101) regulates EZH2 expression in
NSCLC.
Methods: We evaluated the expression of miR-101 and EZH2 in
20 matched NSCLC and adjacent nontumor lung tissues by
reverse-transcriptase polymerase chain reaction and immunohis-
tochemistry, respectively. Luciferase reporter assay was used to
determine whether miR-101 directly targets EZH2. To assess the
effect of miR-101 on NSCLC biological behavior, cell prolifer-
ation, invasion, and response to chemotherapy were analyzed
using NSCLC cells transfected with miR-101 mimics or trans-
fected with specific small interfering RNA to deplete EZH2
(small interfering RNA-EZH2).
Results: Reduced expression of miR-101 was associated with
overexpression of EZH2 in NSCLC tumor tissues. Transfection
of miR-101 mimics significantly suppressed the activity of the
luciferase reporter containing wild type but not mutant EZH2
3-UTR and decreased EZH2 expression in NSCLC cell lines.
Furthermore, enforced expression of miR-101 or knockdown of
EZH2 led to reduced NSCLC cell proliferation and invasion and
sensitized cancer cells to paclitaxel-mediated apoptosis through
inducing expression of the proapoptotic protein Bim.
Conclusions: miR-101 inhibits cell proliferation and invasion and
enhances paclitaxel-induced apoptosis in NSCLC cells, at least in
part, by directly repressing EZH2 expression. Therapeutic strategies
to rescue miR-101 expression or silence EZH2 may be beneficial to
patients with NSCLC in the future.
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Enhancer of zeste homolog 2 (EZH2) is a human homologof the drosophila polycomb group genes, which are criti-
cal for transcriptional regulation by chromatin remodeling,
nucleosome modification, and interaction with other tran-
scription factors.1 EZH2 is believed to function as a histone
methyltransferase for lysine 27 of histone H3 (H3K27) by
forming a multimeric protein complex, called polycomb re-
pressive complex 2 including embryonic ectodern develop-
ment and suppressor of zeste 12 homolog.2 There is increas-
ing evidence that EZH2 possesses oncogenic properties as
overexpression of EZH2 enhances proliferation and invasion
of cancer cells and promotes neoplastic transformation.3–5
Oppositely, depletion of EZH2 in cancer cells leads to re-
duced proliferation, increased apoptosis, and inhibition of
metastatic tumor growth in vivo.3,6–8 EZH2 has been reported
to be overexpressed in a wide variety of human malignancies,
including prostate, breast, endometrial, bladder, gastric, liver,
esophageal, and pancreatic cancers.5,9–15 EZH2 overexpres-
sion correlates with tumor aggression, metastasis, and poor
prognosis.5,9,12,14 Most recently, high EZH2 expression has
been found to be associated with cancer aggressiveness and
may serve as a prognostic marker in non-small cell lung
cancer (NSCLC).16
Given the prominent role of EZH2 in cancer, there is
much interest in understanding the molecular mechanism of
EZH2 up-regulation in cancer. Transcriptionally, EZH2 ex-
pression has been shown to be repressed by tumor suppressor
p53 and transcription factors E2F and E26 transformation-
specific.17–19 In addition, notably recent research shows that
genomic loss of microRNA (miRNA)-101 results in overex-
pression of EZH2 in human tumor samples.20 miRNAs are a
class of short, highly conserved noncoding RNAs that regu-
late target genes through messenger RNA (mRNA) decay or
translation repression.21 Abnormalities of miRNA expression
have been observed in various types of human cancers and
are also related to prognosis and survival of patients with
cancer.22 Emerging data suggest that some miRNAs may
function as oncogenes or tumor suppressor genes and play a
critical role in cancer development.23 Lung cancer is the
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leading cause of cancer-related deaths in the world, and
NSCLC accounts for approximately 80% of all cases. Despite
many advances in diagnosis and treatment of NSCLC over
the past several decades, the overall prognosis for patients
with NSCLC remains poor. Therefore, there is an urgent need
for novel therapeutic approaches for NSCLC. Because high
EZH2 expression is closely correlated with tumor aggressive-
ness and poor prognosis in NSCLC,16 identifying miRNA
that potentially mediates EZH2 expression may provide new
insights into the development of new therapeutic strategies
for NSCLC. In this study, we show that miR-101, negatively
regulating EZH2, inhibits NSCLC cell growth and invasion
and improves cancer cells response to specific chemotherapy
agents.
MATERIALS AND METHODS
Cell Lines and Tissue Samples
H226 (squamous), H358 (bronchioloalveolar adenocar-
cinoma), and A549 (adenocarcinoma) were provided by the
American type culture collection. Human pulmonary giant
cell carcinoma cell 801D was purchased from tumor cell bank
of KeyGen Biotech (Nanging, China). All cells were main-
tained in RPMI-1640 containing 10% fetal bovine serum
(FBS) with 100 IU/ml penicillin and 100 g/ml streptomycin
at 37°C with 5% CO2. Paired NSCLC and adjacent nontumor
lung tissue samples were collected at the time of surgery from
20 patients who underwent primary surgical resection of
NSCLC with informed consent between December 2008 and
March 2009 at Wuhan Union Hospital (Hubei, China). Tissue
samples were fast frozen in liquid nitrogen after resection and
stored at 80°C until use. All specimens were confirmed by
the pathological examinations. No previous chemotherapy or
radiotherapy was administered before resection. The clinical
stage was defined according to American Joint Committee on
Cancer Staging Manual.24 This study was approved by the
Human Research Ethics Committee of Wuhan Union Hospital.
Quantitative Reverse-Transcriptase Polymerase
Chain Reaction Analysis of mRNA and miRNA
Expression
Total RNA from tissues and the cultured cells was
extracted using Trizol (Invitrogen, Carlsbad, CA) for both
miRNA and mRNA analyses. For analysis of mature miR-
101 expression, quantitative reverse-transcriptase polymerase
chain reaction (qRT-PCR) was performed using Hairpin-it
miRNAs qPCR Quantitation Kit (catalog number: QPM-010,
GenePharma, Shanghai, China) according to the manufactur-
er’s instructions. Relative expression was calculated by com-
parative CT method and normalized to the expression of U6
small RNA. EZH2-mRNA was quantified by qRT-PCR using
Quantitect SYBR Green PCR Kit (Qiagen, Hilden, Germany)
and normalized to -actin. PCR primers were as follows:
EZH2, 5-CTTTTCTGTAGGCGATGT-3 (forward) and 5-
ATAGTAAGTGCCAATGAGG-3 (reverse) and -actin, 5-
CAGAGCCTCGCCTTT GCC-3 (forward) and 5-GTCGC-
CCACATAGGAATC-3 (reverse). All qRT-PCRs were
performed in triplicates.
Transfection of miRNA and Small Interfering
RNA
The miR-101 mimics (catalog number: M-01-D) and
small interfering RNA (siRNA) targeting EZH2 (siRNA-
EZH2) (catalog number: A01025) were designed and synthe-
sized by GenePharma (Shanghai, China). Cells at 50 to 60%
confluency were transfected with 100 nmol/liter miR-101
mimics, 100 nmol/liter siRNA-EZH2, or their corresponding
negative controls by Lipofectamine 2000 in Opti-Mem
(Invitrogen). Six hours posttransfection, the culture medium
was replaced with RPMI-1640 containing FBS. Forty-eight
hours after transfection, cells were harvested for analysis. The
transfection efficiency of miR-101 mimics or siRNA-EZH2
was confirmed by qRT-PCR detection of miR-101 or EZH2
mRNA expression (data not shown).
Luciferase Reporter Assay
Luciferase reporter vectors were constructed by cloning
the wild type (wt) or mutant 3-UTR of EZH2 mRNA (see
Supplemental Digital content 1, http://links.lww.com/JTO/A55)
into the XbaI-site of pGL3 vector (Promega, Madison, WI).
A549 cells were transfected with wt or mutant reporter
plasmid vector by Lipofectamine 2000 and then cotransfected
with miR-101 mimics or negative control. After 36 hours,
luciferase assays were performed using the dual luciferase
assay system (Promega). Firefly luciferase activity was nor-
malized to Renilla luciferase activity for each sample.
Cell Proliferation Assay
Cell Counting Kit-8 (Dojindo Laboratories, Ku-
mamoto, Japan) was used for estimating cell viability. In
brief, cells were plated in 96-well plates at 5000 cells/well
and incubated for 48 hours after transfection of 100 nM
miR-101 mimics, 100 nM siRNA-EZH2, or their correspond-
ing negative controls. At the end of incubation, the cell
proliferation reagent WST-8 (10 l) was added to each well
and incubated for 3 hours at 37°C. Viable cell numbers were
evaluated by measurement of optical density (OD) at 450 nm.
Cell Invasion Assay
Cell invasion was assessed using QCM 24-Well Colla-
gen-Based Cell Invasion Assay (Chemicon, Billerica, MA)
according to the manufacturer’s protocol. In brief, 0.3 ml
serum-free medium was added into each insert to rehydrate
the collagen layer for 30 minutes, and then, it was replaced
with 0.3 ml of prepared serum-free cell suspension containing
3.0  105 cells transfected with miR-101 mimics, siRNA-
EZH2, or their corresponding negative controls; 0.5 ml me-
dium containing 10% FBS was added to the lower chamber.
After cells were incubated for 24 hours at 37°C, the nonin-
vaded cells were removed with cotton swabs, and the invaded
cells were stained with cell stain. The stained cells were
dissolved in extraction buffer, and solutions were transferred
to a 96-well culture plate for colorimetric reading of OD at
560 nm. The OD value represents cell invasion ability.
Anticancer Drug-Induced Apoptosis Assay
After 72 hours of transfection with miR-101 mimics,
siRNA-EZH2, or their corresponding negative controls, H358
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and H226 cells were treated with 40 nM paclitaxel (PTX) for
48 hours. Apoptosis was detected by using an annexin V-
FITC kit (Bender Medsystems, Vienna, Austria). Briefly,
cells were incubated with 5 l of annexin V-FITC and 10 l
of propidium iodide in 200 l binding buffer for 15 minutes
at room temperature, immediately followed by flow cytom-
etry. Data were analyzed by Cell Quest software. Cell lysates
were prepared and subjected to Western blot analysis with
antibodies specific for apoptosis-associated proteins.
Western Blot
Proteins from cells were extracted with lysis buffer (10
mmol/liter Tris-HCl, pH 7.4, 1% NP40, 0.1% deoxycholic
acid, 0.1% sodium dodecyl sulfate (SDS), 150 mmol/liter
NaCl, 1 mM ethylene diamine tetraacetic acid, and 1%
Protease Inhibitor Cocktail) (Sigma, St. Louis, MO). Protein
concentrations were determined by protein assay kit (Bio-
Rad, Hercules, CA); 30 g of protein was resolved by
SDS-PAGE using a 10% polyacrylamide gel and transferred
onto a nitrocellulose membrane. The membrane was incubated
overnight at 4°C in blocking buffer (Tris-buffered saline, 0.1%
Tween, and 5% nonfat dry milk) with the following primary
antibodies: anti-EZH2 (Invitrogen), anti-H3K27me3 (Millipore,
Billerica, MA), anti-(poly (ADP-ribose) polymerase) (PARP)
(Santa Cruz Biotechnology, Santa Cruz, CA), anti-Bim (Gen-
Script, Piscataway, NJ), and anti--actin (Cell Signaling Tech-
nology, Beverly, MA). A secondary antibody was incubated
with the membrane for 1 hour after three washes with Tris-
buffered saline and 0.1% Tween. Signals were detected with
ECL detection reagent (Amersham, Piscataway, NJ).
Immunohistochemistry
Four-micrometer-thick formalin-fixed, paraffin-embed-
ded tissue sections were deparaffined in xylene, rehydrated
through graded alcohols, and processed using immunohisto-
chemical SP method. Both negative and positive controls
were set during staining, the former using phosphate-buffered
saline to take the place of first antibody, whereas the latter
using paraffin-embedded slice of prostate cancer known to be
positive for EZH2 expression. Positive cells were defined as
the presence of brown-yellow granules distributed in nucleus
or cytoplasm, with stain intensity higher than the unspecific
background. Percentage of positive cells was grouped as low
(20% of cells positive) or high (20% of cells positive).
Statistical Analysis
Statistical analysis was performed by SPSS software
13.0 (SPSS Inc., Chicago, IL). Values were presented as
mean  standard error of the mean. Differences/correlations
between two groups were assessed by Student’s t test, 2 test,
and Pearson’s correlation test. p less than 0.05 was consid-
ered to be statistically significant.
RESULTS
Decreased Expression of miR-101 is Associated
with EZH2 Overexpression in NSCLC Tissues
The clinicopathologic characteristics in 20 patients
with NSCLC are presented in Table 1. Total RNA was
isolated from matched NSCLC and adjacent nontumor lung
tissues, and the expression levels of miR-101 and EZH2
mRNA were determined by qRT-PCR. In 18 of 20 tumor
samples, miR-101 expression was reduced in tumor tissues
relative to matched nontumor tissues (Figure 1A). Further-
more, 16 tumor samples exhibited up to a twofold reduction
in the level of miR-101. In contrast, EZH2 mRNA was
overexpressed in 95% of tumor samples (19/20 samples)
compared with the nontumor counterparts (Figure 1B). Then,
we examined the association between miR-101 and EZH2
mRNA in these 20 resected tumor samples. A highly signif-
icant negative correlation was observed between miR-101
and EZH2 mRNA, reduced expression of miR-101 correlat-
ing with overexpression of EZH2 mRNA (Figure 1C). To
better substantiate EZH2 overexpression in tumor tissues, we
also conducted immunohistochemical analysis of paraffin-
embedded tumor and nontumor samples from the same 20
patients. Representative examples of EZH2 immunostaining
are displayed in Figure 1D. Tumor samples revealed inten-
sive EZH2 staining; on the contrary, matched nontumor
tissues displayed very weak staining. The result showed that the
expression of EZH2 protein was similarly higher in tumor than
in matched nontumor tissues (Table 2). Among these 20 tumor
samples, 15 showed high-EZH2 protein expression and five
showed low-EZH2 protein expression. We also found that
EZH2 mRNA levels were significantly higher in tumor samples
with high-EZH2 protein expression than in those with low-
EZH2 protein expression (p  0.05), which indicates that the
increase in EZH2 mRNA expression is in keeping with the
increase in EZH2 protein expression in tumor samples.
miR-101 Regulates EZH2 Expression by Binding
the 3-UTR of EZH2 mRNA
To explore whether miR-101 directly targets EZH2, we
created luciferase reporter plasmids by cloning the wt or
mutant 3-untranslated regions (UTR) of EZH2 into pGL3
vector (Figure 2A). The wt or mutant reporter plasmid was
cotransfected into A549 cells along with miR-101 mimics or
the negative control. miR-101 mimics significantly sup-
pressed the luciferase activity of the wt reporter plasmid in
comparison with the negative control. Nevertheless, the lu-
ciferase activity of the mutant reporter plasmid was unaf-
fected by simultaneous transfection with miR-101 mimics
(Figure 2B), indicating that EZH2 is a direct target of miR-
101. To further validate that EZH2 is negatively regulated by
miR-101, we transfected miR-101 mimics into A549, H226,
H358, and 801D cells and examined EZH2 mRNA and
protein levels. The transfection efficiency was confirmed by
TABLE 1. The Clinicopathologic Data of Patients with
NSCLC
Factors
Age (yr) 61.4  7.6
Gender (male/female) 12/8
TNM stage (I/II/III) 2/12/6
Histology (squamous/adenocarcinoma/others) 11/7/2
NSCLC, non-small cell lung cancer; TNM, tumor, node, and metastasis.
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qRT-PCR (see supplemental Figure S1A, Supplemental Dig-
ital Content 2, http://links.lww.com/JTO/A56). miR-101
overexpression led to a significant reduction of endogenous
EZH2 mRNA (Figure 2C) and protein levels (Figures 2D, E)
in NSCLC cell lines. As EZH2 mediates gene repression
mainly by trimethylating H3K27 (H3K27me3), the levels of
H3K27me3 were also evaluated at the same time. As shown
in Figures 2D, E, overexpression of miR-101 in NSCLC cells
concomitantly reduced expression of H3K27me3. These find-
ings suggest that miR-101 may repress EZH2 expression
through miR-101-binding sites at the 3-UTR of EZH2.
Introduction of miR-101 or Specific
Knockdown of EZH2 by siRNA Leads to
Reduced Cell Proliferation and Invasion in
NSCLC Cell Lines
To test whether miR-101 may exert tumor-suppressive
functions by targeting EZH2, we investigated the effects of
overexpression of miR-101 or knockdown of EZH2 on
NSCLC cell proliferation and invasion. H226 and A549 cells
were used for the proliferation assay, and 801D cells were
used for the invasion assay because they displayed good
ability to invade through the collagen-coated membranes.
FIGURE 1. miR-101 and enhancer of zeste homolog 2 (EZH2) are inversely expressed in resected non-small cell lung cancer
(NSCLC) tumors. Total RNA extracted from 20 pairs of matched NSCLC samples was used for quantitative reverse-transcrip-
tase polymerase chain reaction (qRT-PCR) analysis of microRNA (miRNA) and messenger RNA (mRNA) expression. A, Relative
expression of miR-101 in paired T and N. The results were normalized to U6 expression and expressed as fold change in tu-
mor compared with matched N. B, Relative expression of EZH2 mRNA in paired T and N. The results were normalized to
-actin mRNA expression and expressed as fold change in tumor compared with matched N. C, Inverse correlation between EZH2
mRNA (data in panel B) and miR-101(data in panel A) in NSCLC tissues. D, Immunohistochemical staining patterns of EZH2 in
matched NSCLC and adjacent N. T shows high-EZH2 expression (63.4% positive stained cells), and N shows low-EZH2 expression
(7.6% positive stained cells). *p  0.05; **p  0.001; N, nontumor tissue; T, tumor tissue.
TABLE 2. Comparison of the EZH2 Protein Expression





Tumor sample 20 15 (75%) 5 (25%) 0.001
Matched nontumor sample 20 0 (0%) 20 (100%)
Low, positive cells are 20%; high, positive cells are 20% or more; NSCLC,
non-small cell lung cancer; EZH2, enhancer of zeste homolog 2.
Zhang et al. Journal of Thoracic Oncology • Volume 6, Number 4, April 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer674
H226, A549, and 801D cells were transfected with miR-101
mimics, siRNA-EZH2, or their corresponding negative con-
trols. The transfection efficiency was verified by qRT-PCR
(see supplemental Figure S1B, Supplemental Digital Content
2). The results showed that forced expression of miR-101 or
siRNA-mediated EZH2 silencing significantly restrained the
proliferation and invasion of NSCLC cells (Figures 3A, B).
miR-101 Overexpression or EZH2 Silencing
Enhances the Apoptosis of NSCLC Cells in
Response to PTX
It has been shown that miRNAs can affect cancer cells
response to chemotherapy. The PTX is an anticancer drug
widely used in the treatment of NSCLC. It is well established
that PTX-induced cell kill is mainly mediated by apoptosis.
Apoptosis resistance is a significant feature of cancer cells;
therefore, we examined whether miR-101 can alter PTX-in-
duced apoptosis of NSCLC cell lines. Among these four cell
lines, H358 and H226 cells were insensitive to PTX treatment
and, thus, were used for the apoptosis assay. We transfected
H358 and H226 cells for 72 hours with miR-101 mimics or the
corresponding negative control and then treated with 40 nM
PTX for 48 hours. As a parallel control, we directly silenced
EZH2 by transfection of siRNA-EZH2. All transfections were
confirmed by qRT-PCR (see supplemental Figure S1C, Supple-
mental Digital Content 2). The percentage of apoptotic cells was
evaluated by flow cytometric analysis of annexin V-FITC/PI-
stained cells. As shown in Figures 4A, B, silencing of EZH2 or
enforced expression of miR-101 sensitized cancer cells to PTX,
resulting in a significant increase in apoptosis of NSCLC cells.
To clarify the potential mechanism of miR-101-medi-
ated sensitization of NSCLC cells to PTX, we also detected
the expression of a few apoptosis-associated proteins by
Western blot at 48 hours of PTX treatment. EZH2 is known
to inhibit the expression of the proapoptotic BH3-only protein
Bim,25 which is a tumor suppressor in epithelial solid tumors
and which also is a determinant in PTX sensitivity.26 So, the
levels of Bim, EZH2, and cleaved PARP were measured. As
expected, in miR-101 or siRNA-EZH2-transfected cells, the
level of EZH2 was lower than the corresponding control
cells; accordingly, both Bim and cleaved PARP levels were
higher in miR-101 or siRNA-EZH2-transfected cells com-
pared with the corresponding control cells (Figures 4C, D).
DISCUSSION
Although miRNA expression signatures in many types
of human malignancies have been identified, elucidation of
FIGURE 2. miR-101 suppresses enhancer of zeste homolog 2 (EZH2) expression by binding to the EZH2 3-UTR. A, Sche-
matic description of the EZH2 3-UTR with putative binding sites for miR-101. The arrows indicate the mutant nucleotides. B,
Luciferase reporter plasmids containing the wt or mutant EZH2 3-UTR was cotransfected into A549 cells with miR-101 mimics
or the negative control. After transfection for 36 hours, the luciferase activity was measured. The normalized luciferase activity
in the control group was set to 1. miR-101 inhibited wt, but not mutant, EZH2 3-UTR reporter activity. C, Quantitative re-
verse-transcriptase polymerase chain reaction (qRT-PCR) analysis of EZH2 messenger RNA (mRNA) in cells transfected with
miR-101 mimics or the negative control. The results were normalized to -actin mRNA expression and expressed as fold
change relative to the corresponding negative control. D, EZH2 and H3K27me3 protein levels in cells transfected with miR-
101 mimics or the negative control were also detected by Western blot and standardized to -actin protein. The results were
expressed as fold change relative to the corresponding negative control. E, Representative gels display that miR-101 decreases
expression of EZH2 and H3K27me3. All data are representative of three independent experiments. *p  0.05; miR-CON, the
negative control microRNA (miRNA).
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the role of the dysregulation of specific miRNAs in carcino-
genesis remains in the initial stage of development. In this
study, we show that miR-101 is underexpressed in NSCLC
tumor tissues and that it suppresses EZH2 expression by
binding to 3-UTR of EZH2 in NSCLC cells. Moreover, the
current report demonstrates that miR-101 restrains NSCLC
cell proliferation and invasion and sensitizes cancer cells to
PTX-induced apoptosis in vitro by suppression of EZH2
expression.
EZH2 is frequently overexpressed in a wide range of
tumor types and plays a crucial role in tumorigenesis process.
EZH2 has been shown to promote oncogenic transformation
and increase the biologic aggressiveness of cancer cells
through the epigenetic silencing of target genes. Our study
revealed that EZH2 mRNA and protein expression were
significantly higher in NSCLC tumor tissues than in matched
nontumor tissues (Figures 1B, D). Although relatively little is
known about how EZH2 becomes overexpressed in NSCLC,
one such mechanism is through regulation by miRNAs.
Human miRNA genes are frequently located at fragile sites
and cancer-associated genomic regions.27 It has been reported
that abnormal down-regulation of miR-101 could lead to
EZH2 overexpression in prostate and bladder cancer.20,28 In
this study, miR-101 was down-regulated in NSCLC tumor
samples compared with matched nontumor counterparts,
which was consistent with previous studies.29,30 Furthermore,
we observed a highly significant negative correlation between
miR-101 and EZH2 mRNA in tumor samples (Figure 1C).
miR-101, a miRNA commonly down-regulated in cancers,
has been shown to be implicated in cancer-related processes
such as cell growth, invasion, and apoptosis.20,28,31–34 There-
fore, we postulated that miR-101 regulated EZH2 expression
in NSCLC.
This postulation was further confirmed by subsequent
experimental studies on NSCLC cell lines. As shown in
Figure 2B, the activity of the luciferase reporter with wt but
not mutant EZH2 3-UTR was significantly inhibited in A549
cells transfected with miR-101 mimics compared with the
negative control. In addition, transfection of NSCLC cells
with miR-101 mimics caused a dramatic decrease in EZH2
mRNA and protein levels and concomitantly reduced
H3K27me3 expression. These findings provide strong evi-
dence that miR-101 down-regulates EZH2 expression by
directly targeting the 3-UTR of EZH2 mRNA. Although we
prove that EZH2 is a direct target of miR-101 in NSCLC, it
is still unknown whether miR-101 may exert tumor-suppres-
sive functions in NSCLC. Accordingly, we investigated the
effect of miR-101 on the biological behavior of NSCLC cells
in vitro. We observed that overexpression of miR-101 inhib-
ited the proliferation and invasion of NSCLC cells. More-
over, knockdown of EZH2 by siRNA in NSCLC cells also
resulted in reduced cell proliferation and invasion. These data
indicate that suppression of NSCLC cell proliferation and
invasion by miR-101 may be mediated, at least in part,
through down-regulation of EZH2.
The treatment of many malignancies, including
NSCLC, is usually impeded by the intrinsic or acquired
resistance to the anticancer drugs used. Deregulated apoptosis
is a common cause of cancer therapy chemoresistance be-
cause the apoptosis-inducing ability of anticancer agents may
at least partly account for drug efficacy. NSCLC is charac-
terized by its poor survival and resistance to chemotherapy-
induced apoptosis both in vitro and in vivo.35–37 PTX, which
is extensively used to treat NSCLC, kills tumor cells chiefly
through inducing apoptosis. Therefore, the role of miR-101 in
regulating PTX-induced apoptosis in NSCLC cells deserves
investigation. In this study, miR-101 overexpression or
siRNA-mediated EZH2 depletion in NSCLC cells stimulated
PTX-induced apoptosis and led to a decrease in EZH2 protein
and an increase in Bim protein. Previous studies demon-
strated that enforced expression of Bim increased the suscep-
tibility of NSCLC cells to PTX-mediated killing, and knock-
FIGURE 3. miR-101 overexpression or enhancer of zeste homolog 2 (EZH2) knockdown inhibits non-small cell lung cancer
(NSCLC) cell proliferation and invasion. Cells transfected with 100 nmol/liter miR-101 mimics or small interfering RNA (siRNA)-
EZH2, compared with the corresponding negative controls, were used for the proliferation and invasion assay. A, Cell proliferation
was analyzed by CCK-8 assay in H226 and A549 cells. The results were expressed as fold change relative to the corresponding neg-
ative controls. B, Cell invasion was determined in 801D cells using Chemicon cell invasion assay. The results were expressed as fold
change relative to the corresponding negative controls. All data are representative of three independent experiments. *p  0.05;
**p  0.001; miR-CON, the negative control microRNA (miRNA); si-CON, the negative control siRNA.
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down of Bim reduced PTX-mediated killing of NSCLC cells,
suggesting that Bim is an important molecular link between
PTX and apoptosis.38 EZH2 has been shown to regulate
apoptosis through epigenetically modulating Bim expres-
sion.25 Together with these previous research achievements,
our results indicate that EZH2 repression by miR-101 induces
Bim expression and, thus, enhances PTX-induced apoptosis
in NSCLC cells. Certainly, as a specific miRNA has the
potential to target multiple genes, miR-101 may function
through cooperative regulation of its other target genes.
Nevertheless, other targets of miR-101 besides EZH2 still
need to be identified in NSCLC.
In conclusion, miR-101, which is down-regulated in
NSCLC tumor tissues, inhibits cellular proliferation and
invasion and increases apoptosis induced by PTX in
NSCLC cell lines. These effects are at least partially due to
direct suppression of EZH2 by miR-101. Our findings
imply that therapeutic strategies aimed at restoration of
miR-101 expression or depletion of EZH2 may be benefi-
cial to patients with NSCLC.
FIGURE 4. Overexpression of miR-101 or silencing of enhancer of zeste homolog 2 (EZH2) sensitizes non-small cell lung can-
cer (NSCLC) cells to PTX-induced apoptosis. H358 and H226 cells transfected for 72 hours with miR-101 mimics, small inter-
fering RNA (siRNA)-EZH2, or their corresponding negative controls, and then treated with 40 nM PTX for 48 hours, were har-
vested for apoptosis analysis. A, Apoptosis was measured by flow cytometry for annexin V-FITC/PI double staining. The results
were expressed as percentages of the corresponding negative controls. B, Representative cytograms show that miR-101 over-
expression or EZH2 depletion augments PTX-induced apoptosis. C, Cell lysates were prepared for Western blot analysis of
EZH2, Bim, and cleaved PARP expression. The results were normalized to -actin protein expression and expressed as fold
change relative to the corresponding negative controls. D, Representative immunoblots show that EZH2 suppression by miR-
101 or siRNA-EZH2 induces Bim and cleaved PARP expression. All data are representative of three independent experiments.
*p  0.05; **p  0.001; miR-CON, the negative control microRNA (miRNA); si-CON, the negative control siRNA.
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